atrasentan has been researched along with Prostatic Hyperplasia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bova, GS; Chan-Tack, K; Hedican, SP; Magnuson, SR; Nelson, JB; Opgenorth, TJ; Simons, JW | 1 |
1 other study(ies) available for atrasentan and Prostatic Hyperplasia
| Article | Year |
|---|---|
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.
Topics: Apoptosis; Atrasentan; Base Sequence; Cell Division; Cell Line; Culture Media, Serum-Free; DNA Primers; DNA, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Epidermal Growth Factor; Fibroblast Growth Factor 2; Gene Expression; Growth Substances; Humans; Immunohistochemistry; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Male; Mitotic Index; Molecular Sequence Data; Neoplasm Metastasis; Platelet-Derived Growth Factor; Polymerase Chain Reaction; Prostate; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Pyrrolidines; Receptor, Endothelin B; Receptors, Endothelin; RNA, Messenger; Tumor Cells, Cultured | 1996 |